Key facts
- 52-week range (closes)
- $70.08 – $110.60 Lowest close Mar 27, 2026, highest Jul 21, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Mar 4, 1957 · All S&P 500 changes
CVS Health (CVS) is trading up at $94.56 (+2.02%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
CVS Health revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $177.5B | $184.8B | $194.6B | $256.8B | $268.7B | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Growth (year over year) | +15.8% | +4.1% | +5.3% | +32.0% | +4.6% | +8.7% | +10.4% | +10.9% | +4.2% | +7.8% |
| Gross profit | $28.9B | $28.5B | $38.1B | $98.1B | $104.7B | $116.3B | $125.6B | $140.7B | $166.5B | $180.9B |
| Gross margin | 16.3% | 15.4% | 19.6% | 38.2% | 39.0% | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% |
| Operating income | $10.4B | $9.54B | $4.02B | $12.0B | $13.9B | $13.3B | $7.95B | $13.7B | $8.52B | $4.66B |
| Operating margin | 5.8% | 5.2% | 2.1% | 4.7% | 5.2% | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% |
| Net income | $5.32B | $6.62B | −$594.0M | $6.63B | $7.18B | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B |
| Net margin | 3.0% | 3.6% | −0.3% | 2.6% | 2.7% | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| EPS (diluted) | $4.90 | $6.44 | −$0.57 | $5.08 | $5.46 | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.37B | $1.70B | $4.06B | $5.68B | $7.85B | $9.41B | $12.9B | $8.20B | $8.59B | $8.45B |
| Total assets | $94.5B | $95.1B | $216.7B | $222.4B | $230.7B | $233.0B | $228.3B | $249.7B | $253.2B | $253.5B |
| Total liabilities | $57.6B | $57.4B | $157.9B | $158.3B | $161.0B | $157.6B | $156.5B | $173.1B | $177.5B | $178.2B |
| Long-term debt | $25.6B | $22.2B | $71.3B | $64.7B | $59.2B | $52.0B | $50.5B | $58.6B | $60.5B | $60.5B |
| Shareholders' equity | $36.8B | $37.7B | $58.4B | $63.9B | $69.4B | $75.1B | $71.5B | $76.5B | $75.6B | $75.2B |
| Cash flow | ||||||||||
| Operating cash flow | $10.1B | $8.01B | $8.87B | $12.8B | $15.9B | $18.3B | $16.2B | $13.4B | $9.11B | $10.6B |
| Capital expenditure | $2.22B | $1.92B | $2.04B | $2.46B | $2.44B | $2.52B | $2.73B | $3.03B | $2.78B | $2.83B |
| Free cash flow | $7.92B | $6.09B | $6.83B | $10.4B | $13.4B | $15.7B | $13.4B | $10.4B | $6.33B | $7.81B |
| Dividends paid | $1.84B | $2.05B | $2.04B | $2.60B | $2.62B | $2.63B | $2.91B | $3.13B | $3.37B | $3.40B |
| Share buybacks | $4.46B | $4.36B | $0 | $0 | $0 | $0 | $3.50B | $2.01B | $3.02B | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $95.4B | $97.7B | $94.6B | $98.9B | $102.9B | $105.7B | $100.4B | $106.1B |
| Growth (year over year) | +6.3% | +4.2% | +7.0% | +8.4% | +7.8% | +8.2% | +6.2% | +7.3% |
| Gross profit | $42.5B | $42.4B | $43.5B | $44.9B | $45.8B | $46.6B | $45.0B | $47.2B |
| Gross margin | 44.5% | 43.4% | 46.0% | 45.4% | 44.5% | 44.1% | 44.8% | 44.5% |
| Operating income | $832.0M | $2.37B | $3.37B | $2.38B | −$3.21B | $2.11B | $4.68B | $4.70B |
| Operating margin | 0.9% | 2.4% | 3.6% | 2.4% | −3.1% | 2.0% | 4.7% | 4.4% |
| Net income | $87.0M | $1.64B | $1.78B | $1.02B | −$3.98B | $2.94B | $2.94B | $2.98B |
| Net margin | 0.1% | 1.7% | 1.9% | 1.0% | −3.9% | 2.8% | 2.9% | 2.8% |
| EPS (diluted) | $0.07 | $1.30 | $1.41 | $0.80 | −$3.13 | $2.31 | $2.30 | $2.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.88B | $8.59B | $10.1B | $11.8B | $9.10B | $8.45B | $9.54B | $11.3B |
| Total assets | $252.4B | $253.2B | $255.6B | $258.3B | $255.3B | $253.5B | $253.0B | $253.8B |
| Total liabilities | $177.3B | $177.5B | $178.5B | $180.8B | $182.2B | $178.2B | $175.3B | $173.9B |
| Long-term debt | $59.8B | $60.5B | $59.0B | $57.3B | $60.5B | $60.5B | $60.5B | $59.5B |
| Shareholders' equity | $74.9B | $75.6B | $76.9B | $77.4B | $72.9B | $75.2B | $77.5B | $79.7B |
| Cash flow | ||||||||
| Operating cash flow | −$745.0M | $1.86B | $4.56B | $1.90B | $796.0M | $3.39B | $4.25B | $6.34B |
| Capital expenditure | $670.0M | $768.0M | $743.0M | $607.0M | $698.0M | $784.0M | $849.0M | $691.0M |
| Free cash flow | −$1.42B | $1.09B | $3.81B | $1.29B | $98.0M | $2.61B | $3.40B | $5.65B |
| Dividends paid | $837.0M | $838.0M | $840.0M | $866.0M | $846.0M | $845.0M | $847.0M | $878.0M |
| Share buybacks | −$1.00M | $0 | $0 | $0 | $0 | $0 | — | — |
From CVS Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
CVS Health vs the Health Care sector and the S&P 500
CVS Health's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | CVS Health | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +7.8% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 0.4% | 13.1% | 13.0% |
| Dividend per share, latest fiscal year | $2.66 | $2.43 | $2.40 |
| Share price change, 1 year | +12.4% | +19.8% | +5.6% |
CVS Health: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, CVS Health included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About CVS Health
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.
Source: Wikipedia — CVS Health
- Headquarters
- Woonsocket, Rhode Island From SEC filings, Oct 2026
Recent News (20)
-
Alaska Airlines names Amaresh Siva Chief Information Technology Officer Veteran technology executive will lead Alaska's enterprise technology, data, digital, cybersecurity and AI strategy, focused on operational reliability, modernization and long-term growth Siva brings …
-
CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans Stocktwits
-
CVS Health collaborates with The Midlife Collective to redefine a woman's midlife health journey New research study will explore the realities and opportunities of midlife and inform an upcoming documentary WOONSOCKET, R.I., Oct 15, 2026 /PRNewswire/ -- CVS Health®(NYSE: CVS) today announced a ne…
-
MinuteClinic earns seventh consecutive Joint Commission accreditation, including first evaluation under Medical Center standards Approximately 80 percent of surveyed locations offer primary care, now available at more than 65 percent of MinuteClinic locations. WOONSOCKET, R.I., Oct 14, 2026 /PRNewswire/ -- CVS Health® (NYSE: CV…
-
CVS to pay $315M settlement over allegations of illegally filling opioid prescriptions The Justice Department (DOJ) announced Tuesday that CVS Health has agreed to pay $315 million to settle lawsuits alleging the company illegally filled prescriptions for opioids and other controlled su…
-
CVS settles US Justice Department case over opioid prescriptions for $315 million
CVS settles US Justice Department case over opioid prescriptions for $315 million
-
-
-
Humana Soars 16% on Improved Medicare Advantage Star Ratings; CVS Slides 3%, UnitedHealth Holds Steady - 24/7 Wall St. Humana Soars 16% on Improved Medicare Advantage Star Ratings; CVS Slides 3%, UnitedHealth Holds Steady 24/7 Wall St.
-
3 US Dividend Stocks For Higher Rates Including CVS Health Stock 3 US Dividend Stocks For Higher Rates Including CVS Health Stock Simply Wall Street
-
Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience HARTFORD, Conn., Oct 8, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars…
-
-
-
After-Hours Movers: T, VZ, TMUS, SPCX, HUM, ALHC, CVS, CLOV, UNH, AXP
After-Hours Movers: T, VZ, TMUS, SPCX, HUM, ALHC, CVS, CLOV, UNH, AXP
-
-
-
Cardinal Health rises on extended CVS distribution deal
Cardinal Health rises on extended CVS distribution deal
-
McKesson extends CVS deal; shares rise
McKesson extends CVS deal; shares rise
-
-
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health…
More Health Care stocks
- CNC Centene Corporation
- COO Cooper Companies (The)
- COR Cencora
- CRL Charles River Laboratories
- DGX Quest Diagnostics
- DHR Danaher Corporation
- DVA DaVita
- DXCM Dexcom